Short answer
Lilly (Eli) (LLY) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $19.8B (up 55.5% year over year) with net income of $7.4B.
Q1 2026 key financials · XBRL
- Revenue
- $19.8B
- +55.5% YoY
- Net income
- $7.4B
- +168.0% YoY
- EPS (diluted)
- $8.26
- +169.9% YoY
Source: XBRL data from the Lilly (Eli) (LLY) Q1 2026 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19,799 million, up 56% from $12,729 million YoY, driven by Mounjaro and Zepbound volume
- Net income $7,396 million, up 168% from $2,759 million YoY
- Mounjaro and Zepbound best-performing products, representing 65% of total revenue
- Near-term performance dependent on orforglipron approvals and incretin channel and market uptake
- Headwinds from lower realized prices, pricing agreements, tariffs, counterfeit products, and cost-containment policies
Risk Factors
- No material changes to risk factors since December 31, 2025 Form 10-K
- Carried-forward risks include pharmaceutical competition, pricing pressure, regulatory changes, product liability, and supply-chain disruption
- No newly triggered regulatory, legal, or compliance risk identified this quarter
- $2.3 billion share repurchases during quarter, reducing remaining authorization to $8.573 billion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.